187 related articles for article (PubMed ID: 36836825)
1. Predictors of Progression and Mortality in Patients with Chronic Hypersensitivity Pneumonitis: Retrospective Analysis of Registry of Fibrosing Interstitial Lung Diseases.
Trushenko NV; Suvorova OA; Pershina ES; Nekludova GV; Chikina SY; Levina IA; Chernyaev AL; Samsonova MV; Tyurin IE; Mustafina MK; Yaroshetskiy AI; Nadtochiy NB; Merzhoeva ZM; Proshkina AA; Avdeev SN
Life (Basel); 2023 Feb; 13(2):. PubMed ID: 36836825
[TBL] [Abstract][Full Text] [Related]
2. Predictors of Pulmonary Hypertension and Right Ventricular Dysfunction in Patients with Hypersensitivity Pneumonitis.
Trushenko NV; Suvorova OA; Nekludova GV; Levina IA; Chikina SY; Nikolenko AM; Tsareva NA; Volkov AV; Yaroshetskiy AI; Merzhoeva ZM; Nuralieva GS; Avdeev SN
Life (Basel); 2023 Jun; 13(6):. PubMed ID: 37374130
[TBL] [Abstract][Full Text] [Related]
3. Criteria for progressive fibrotic hypersensitivity pneumonitis in a Portuguese patient cohort.
Seixas E; Ferreira M; Serra P; Aguiar R; Cunha I; Ferreira PG
Afr J Thorac Crit Care Med; 2022; 28(4):. PubMed ID: 36817315
[TBL] [Abstract][Full Text] [Related]
4. Care patterns of patients with chronic fibrosing interstitial lung disease (ILD) with a progressive phenotype.
Nili M; Singer D; Hanna M
BMC Pulm Med; 2022 Apr; 22(1):153. PubMed ID: 35459138
[TBL] [Abstract][Full Text] [Related]
5. Diagnosis, course and management of hypersensitivity pneumonitis.
Hamblin M; Prosch H; Vašáková M
Eur Respir Rev; 2022 Mar; 31(163):. PubMed ID: 35140104
[TBL] [Abstract][Full Text] [Related]
6. Nintedanib: A Review in Fibrotic Interstitial Lung Diseases.
Lamb YN
Drugs; 2021 Apr; 81(5):575-586. PubMed ID: 33765296
[TBL] [Abstract][Full Text] [Related]
7. Nintedanib in patients with progressive fibrosing interstitial lung diseases-subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial.
Wells AU; Flaherty KR; Brown KK; Inoue Y; Devaraj A; Richeldi L; Moua T; Crestani B; Wuyts WA; Stowasser S; Quaresma M; Goeldner RG; Schlenker-Herceg R; Kolb M;
Lancet Respir Med; 2020 May; 8(5):453-460. PubMed ID: 32145830
[TBL] [Abstract][Full Text] [Related]
8. Possible value of antifibrotic drugs in patients with progressive fibrosing non-IPF interstitial lung diseases.
Torrisi SE; Kahn N; Wälscher J; Sarmand N; Polke M; Lars K; Eichinger M; Heussel CP; Palmucci S; Sambataro FM; Sambataro G; Sambataro D; Vancheri C; Kreuter M
BMC Pulm Med; 2019 Nov; 19(1):213. PubMed ID: 31718637
[TBL] [Abstract][Full Text] [Related]
9. Clinical Overview of Progressive Fibrotic Interstitial Lung Disease.
Case AH
Front Med (Lausanne); 2022; 9():858339. PubMed ID: 35372405
[TBL] [Abstract][Full Text] [Related]
10. Predictors of survival in coexistent hypersensitivity pneumonitis with autoimmune features.
Adegunsoye A; Oldham JM; Demchuk C; Montner S; Vij R; Strek ME
Respir Med; 2016 May; 114():53-60. PubMed ID: 27109811
[TBL] [Abstract][Full Text] [Related]
11. Progressive Fibrosing Interstitial Lung Diseases: Prevalence and Characterization in Two Italian Referral Centers.
Faverio P; Piluso M; De Giacomi F; Della Zoppa M; Cassandro R; Harari S; Luppi F; Pesci A
Respiration; 2020; 99(10):838-845. PubMed ID: 33264777
[TBL] [Abstract][Full Text] [Related]
12. Claims-based Prevalence of Disease Progression among Patients with Fibrosing Interstitial Lung Disease Other than Idiopathic Pulmonary Fibrosis in the United States.
Singer D; Bengtson LGS; Conoscenti CS; Laouri M; Shetty SS; Anderson AJ; Brown KK
Ann Am Thorac Soc; 2022 Jul; 19(7):1112-1121. PubMed ID: 35015982
[No Abstract] [Full Text] [Related]
13. CCL18 in serum, BAL fluid and alveolar macrophage culture supernatant in interstitial lung diseases.
Cai M; Bonella F; He X; Sixt SU; Sarria R; Guzman J; Costabel U
Respir Med; 2013 Sep; 107(9):1444-52. PubMed ID: 23831213
[TBL] [Abstract][Full Text] [Related]
14. Real-life prevalence of progressive fibrosing interstitial lung diseases.
Gagliardi M; Berg DV; Heylen CE; Koenig S; Hoton D; Tamirou F; Pieters T; Ghaye B; Froidure A
Sci Rep; 2021 Dec; 11(1):23988. PubMed ID: 34907290
[TBL] [Abstract][Full Text] [Related]
15. Association between Pepsin in Bronchoalveolar Lavage Fluid and Prognosis of Chronic Fibrosing Interstitial Lung Disease.
Kim Y; Lee YJ; Cho YJ; Yoon HI; Lee JH; Lee CT; Park JS
Tohoku J Exp Med; 2018 Nov; 246(3):147-153. PubMed ID: 30405002
[TBL] [Abstract][Full Text] [Related]
16. Automated computer-based CT stratification as a predictor of outcome in hypersensitivity pneumonitis.
Jacob J; Bartholmai BJ; Rajagopalan S; Karwoski R; Mak SM; Mok W; Della Casa G; Sugino K; Walsh SLF; Wells AU; Hansell DM
Eur Radiol; 2017 Sep; 27(9):3635-3646. PubMed ID: 28130610
[TBL] [Abstract][Full Text] [Related]
17. Clusters of comorbidities in fibrotic hypersensitivity pneumonitis.
Prior TS; Wälscher J; Gross B; Bendstrup E; Kreuter M
Respir Res; 2022 Dec; 23(1):368. PubMed ID: 36539821
[TBL] [Abstract][Full Text] [Related]
18. The extended utility of antifibrotic therapy in progressive fibrosing interstitial lung disease.
Sarkar P; Avram C; Chaudhuri N
Expert Rev Respir Med; 2020 Oct; 14(10):1001-1008. PubMed ID: 32567402
[TBL] [Abstract][Full Text] [Related]
19. [Use of antifibrotic drugs in interstitial lung disease].
Kreutz CP; Gesierich W; Behr J; Kneidinger N
Dtsch Med Wochenschr; 2022 Oct; 147(21):1383-1390. PubMed ID: 36279864
[TBL] [Abstract][Full Text] [Related]
20. Progressive fibrosing interstitial lung diseases: A new concept and indication of nintedanib.
Makino S
Mod Rheumatol; 2021 Jan; 31(1):13-19. PubMed ID: 32964766
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
